MiNK Therapeutics (INKT) Institutional Ownership $14.82 -1.16 (-7.26%) Closing price 04:00 PM EasternExtended Trading$15.09 +0.27 (+1.82%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for MiNK Therapeutics (NASDAQ:INKT)CurrentInstitutional OwnershipPercentage2.87%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$1.35M Get INKT Insider Trade Alerts Want to know when executives and insiders are buying or selling MiNK Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data INKT Institutional Buying and Selling by Quarter MiNK Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/7/2025 Longbow Finance SA16,667$144K0.0%-90.0%0.420% 2/13/2025 Renaissance Technologies LLC101,707$71K0.0%-4.7%2.566% 2/12/2025 Geode Capital Management LLC96,113$67K0.0%-1.9%2.427% 2/7/2025 HighTower Advisors LLC50,676$35K0.0%-2.0%1.280% 8/9/2024 Renaissance Technologies LLC127,841$121K0.0%+21.5%0.368% 11/14/2023 Oracle Investment Management Inc.36,898$41K0.0%-26.9%0.107% 8/14/2023 Oracle Investment Management Inc.50,461$106K0.1%N/A0.146% 8/14/2023 Deep Track Capital LP324,867$682K0.0%N/A0.941% 8/11/2023 Artal Group S.A.228,216$479K0.0%-21.2%0.663% 7/27/2023 Virtu Financial LLC14,232$30K0.0%N/A0.041% 2/10/2023 StoneX Group Inc.17,821$47K0.0%N/A0.053% 11/4/2022First Republic Investment Management Inc.81,500$172K0.0%N/A0.243% 2/15/2022 Sofinnova Investments Inc.345,499$1.54M0.1%N/A1.031% (Data available from 1/1/2016 forward) INKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of INKT shares? During the previous two years, the following institutional investors and hedge funds held shares of MiNK Therapeutics shares: Longbow Finance SA ($144K), Renaissance Technologies LLC ($71K), Geode Capital Management LLC ($67K), and Oracle Investment Management Inc. ($41K), HighTower Advisors LLC ($35K).Learn more on MiNK Therapeutics' institutional investors. What percentage of MiNK Therapeutics' stock is owned by institutional investors? 2.87% of MiNK Therapeutics' stock is owned by institutional investors. Learn more on INKT's institutional investor holdings. Which institutional investors have been buying MiNK Therapeutics' stock? The following institutional investors have purchased MiNK Therapeutics' stock in the last 24 months: Renaissance Technologies LLC ($22.61K). Which of MiNK Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold MiNK Therapeutics stock in the last 24 months: Longbow Finance SA ($150.00K), Renaissance Technologies LLC ($4.98K), Geode Capital Management LLC ($1.87K), and HighTower Advisors LLC ($1.05K). How much institutional selling is happening at MiNK Therapeutics? Institutional investors have sold a total of 157,899 shares in the last 24 months. This volume of shares sold represents approximately $1.35M in transactions. Related Companies Mereo BioPharma Group Institutional Ownership Neumora Therapeutics Institutional Ownership Puma Biotechnology Institutional Ownership Galectin Therapeutics Institutional Ownership Allogene Therapeutics Institutional Ownership Tvardi Therapeutics Institutional Ownership Alumis Institutional Ownership Editas Medicine Institutional Ownership scPharmaceuticals Institutional Ownership Prima BioMed Institutional Ownership This page (NASDAQ:INKT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access